
All records · Back to the record · Dossier (sources.md) · Terminology · Report a problem · Comments
Everything a reviewer needs to judge, gathered from the record. Release status: draft.
| Review | Status | Reviewer | Date | Notes |
|---|---|---|---|---|
| schema validation | passed | scripts/build.ps1 -Conformance | 2026-11-02 | JSON Schema, project checks, CDA XSD, C-CDA R2.1 Schematron, FHIR R4, and US Core 6.1.0 with zero errors. |
| clinical review | in_progress | Reopened 2026-11-03: focused visits, a preventive visit, a sick visit, and the consultation were added. The 2026-11-02 approval covered the earlier content. | ||
| provenance review | passed | Pat Rutledge, Aether Forge | 2026-11-02 | Accepted as sufficient for release. Open items at acceptance: Primary letters, NPS sources, and PubMed abstracts logged; full texts of retrospective-diagnosis papers not reviewed. |
| safe messaging review | in_progress | Reopened 2026-11-03: focused visits, a preventive visit, a sick visit, and the consultation were added. The 2026-11-02 approval covered the earlier content. |
Checks the monitoring protocol called for that the schedule did not perform. Each is recorded with its outcome and corrective action, never filled with an invented result.
| Visit | Measure | Interval | What happened |
|---|---|---|---|
| 2026-08-11 Progress note 02 (C-CDA) | PHQ-9 at four weeks | At least monthly during acute treatment | Not done: the care plan set the first review at six weeks, so no score was taken at four weeks, a deviation from the protocol. No harm resulted: today's score has fallen 5 points and he has no suicidal thoughts. Corrective action: a nurse telephone PHQ-9 in about four weeks, so the seven weeks to the twelve-week review are not left unmeasured |
| 2026-08-11 Progress note 02 (C-CDA) | Sertraline tolerability check two weeks after starting | 2 weeks after starting and after each dose change | Not done: no contact was scheduled between the intake visit and today, a deviation from the protocol, which also calls for closer contact in the first weeks of an antidepressant. No harm resulted judging by today's review: the mild nausea settled by the third week, and he has had no restlessness, agitation, or suicidal thoughts. Corrective action: a nurse telephone check one to two weeks after any future start or dose change is now in his plan |
| 2026-08-11 Progress note 02 (C-CDA) | Mood Disorder Questionnaire (bipolar screen) | Once at the initial depression workup | Not given at intake, a deviation from the protocol. Dr. Natarajan's interview today found no past periods of elevated or irritable mood, reduced need for sleep, or racing thoughts, so bipolar disorder is not suspected, and no harm resulted: he has had no activation on sertraline. The questionnaire will be used if hypomanic features appear |
| 2026-09-30 Progress note 03 (C-CDA) | Interim PHQ-9 by nurse telephone check | At least monthly during acute treatment | The telephone PHQ-9 planned at the six-week visit for about four weeks later was not made, so seven weeks passed without a score, a second deviation from the monthly cadence. No harm resulted: he improved steadily and reports no suicidal thoughts in the interval. Corrective action: continuation-phase PHQ-9s every two to four weeks are booked, the first at his preventive visit in about four weeks |
| Visit | Type | Item | Status | Detail |
|---|---|---|---|---|
| 2026-10-27 Progress note 05 (C-CDA) | Prevention | HIV screening | Ordered | One-time antigen and antibody test, with his consent; no prior result on record |
| 2026-10-27 Progress note 05 (C-CDA) | Prevention | Hepatitis C screening | Ordered | One-time antibody test with reflex RNA, with his consent |
| 2026-10-27 Progress note 05 (C-CDA) | Prevention | Hepatitis B screening | Ordered | One-time triple panel (surface antigen, surface antibody, and core antibody) |
| Claim | Statement | Certainty |
|---|---|---|
| CLM-0006 | Lincoln’s recurrent melancholy is retrospectively interpreted by modern clinicians as chronic depression that did not prevent him from leading the nation. | probable |
| CLM-0008 | Marfan syndrome, or another inherited marfanoid disorder such as multiple endocrine neoplasia type 2B, has been proposed retrospectively from Lincoln’s build; the diagnosis is disputed and has never been genetically confirmed. | disputed |
| CLM-0012 | Lincoln’s November 1863 illness after the Gettysburg Address has been retrospectively interpreted as unmodified smallpox, more serious than his physicians reported publicly; the interpretation is disputed. | possible |
| Claim | Grade | Statement |
|---|---|---|
| CLM-0002 | D | Lincoln was mortally wounded at Ford’s Theatre on the night of April 14, 1865, and died at the Petersen House at 7:22 a.m. on April 15, 1865, aged 56. |
| Problem | Code | Verification | Reason |
|---|---|---|---|
| Major depressive disorder, single episode, moderate; synthetic modern diagnosis linked to documented low mood and its retrospective interpretation | F32.1 | provisional | Synthetic active diagnosis for the teaching episode; the historical depression label remains R. |
Every note in the record, with its type. All clinical content is synthetic.
None.